Biosimilars in Oncology: A Payor, Provider, and Community/C-Suite Perspective

Panel Discussion, Kevin Knopf

CE Synergy, 05/06/2021

  1. Review updates on the current state of affairs for the global and US oncology biosimilar market.
  2. Identify existing and/or anticipated barriers to adoption of biosimilars from various stakeholders (payor, provider, c-suite, community)
  3. Discuss strategies and best practice solutions to help optimize biosimilar adoption
  4. Describe current and future policies or regulations impacting biosimilar ecosystem